论文部分内容阅读
在Ⅱ型糖尿病临床治疗中,磺脲类药物继发性失效是常见而棘手的问题之一,其年发生率为5%~10%,连续用药5 a后,发生率可达40%~50%,磺脲类药物是Ⅱ型糖尿病人经常服用的药物之一。磺脲类药物继发性失效后引起的高血糖造成糖尿病患者精代谢、脂代谢、蛋白质代谢的紊乱,其后果是严重的。为了控制这部分患者的血糖,我们采用诺和灵30 R胰岛素治疗磷脲类药物继发性失效的Ⅱ型糖尿病患者,有效的降低了血糖,改善了患者的临床症状,取得了满意的疗效,现报告如下。
In the clinical treatment of type II diabetes, sulfonylurea secondary failure is a common and difficult problem, the annual incidence of 5% to 10%, 5d after continuous use, the incidence of up to 40% to 50 %, Sulfonylureas are type II diabetes often take one of the drugs. Sulfonylureas caused by secondary failure of high blood sugar caused by hyperlipidemia in patients with metabolic, lipid metabolism, protein metabolism disorder, the consequences are serious. In order to control the blood sugar of this part of patients, we use Novolin 30 R insulin to treat type 2 diabetes patients with secondary failure of phosphate-ureas, effectively reducing blood sugar, improving the patient’s clinical symptoms and achieving satisfactory results. The report is as follows.